Lipella Pharmaceuticals (LIPO) Competitors

ZyVersa Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. ZyVersa Therapeutics' return on equity of -109.54% beat Lipella Pharmaceuticals' return on equity.

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lipella Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

ZyVersa Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Lipella Pharmaceuticals has a net margin of -988.83% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Lipella Pharmaceuticals' return on equity.

23.9% of Onconetix shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lipella Pharmaceuticals has lower revenue, but higher earnings than Onconetix. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

In the previous week, Onconetix's average media sentiment score of 1.87 beat Lipella Pharmaceuticals' score of 0.00 indicating that Onconetix is being referred to more favorably in the media.

Onconetix has a beta of 2.72, meaning that its stock price is 172% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 2,623.74%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Lipella Pharmaceuticals.

In the previous week, Sunshine Biopharma had 4 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 4 mentions for Sunshine Biopharma and 0 mentions for Lipella Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.36 beat Lipella Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lipella Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Lipella Pharmaceuticals has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Sunshine Biopharma has a net margin of -18.45% compared to Lipella Pharmaceuticals' net margin of -988.83%. Sunshine Biopharma's return on equity of -27.75% beat Lipella Pharmaceuticals' return on equity.

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Lipella Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat ASLAN Pharmaceuticals' return on equity.

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.